CHAIR
:
SPEAKER
(S):
Julie Cherrington, PhD, President , Phenomix Corporation
Giora Feuerstein, MD, Assistant Vice President Translational Research , Wyeth Research
John Gilly, PhD, Deputy Director (Contractor), Biopharmaceutical Development Program , SAIC-Frederick, Inc.
William Manning, Jr., PhD, Associate Director, Pharmacodynamic Biomarkers , Genentech
Dirk Mendel, PhD, Vice President, Pharmacology and Preclinical PK/PD, KAI Pharmaceuticals, Inc
Description
Interest in translational medicine is growing because of its crucial role as a bidirectional bridge between advances in basic drug research and clinical development. To reduce the number of compounds that fail in early trials, and accelerate the development of safe and effective therapies to patients, translational research should be thought of as a two-way process: It is equally important to go from the bench to the bedside as it is to go from the bedside back to the bench.
Objective 1:Teach new strategies for optimizing drug candidates prior to starting clinical trials.
Objective 2:Explore routes and resources for industry to work with the National Cancer Institute to advance molecules into the clinic.
Objective 3:"Illustrate by example successful methods to create drugs, not
compounds."